UBS: Raises Target Price for WuXi Biologics (02269.HK) to 51.1 Hong Kong Dollars, Maintains "Buy" Rating

According to Wise Fund Financial APP, UBS released a research report stating that it has raised its revenue forecast for WuXi Biologics (02269.HK) for fiscal years 2027 to 2029, and has raised its target price from 49.3 Hong Kong dollars to 51.1 Hong Kong dollars, based on discounted cash flow (DCF) calculations. It maintains a "buy" rating.